Inspection Record
View the regulator's official source The source document is always the basis for judgement.
The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080). The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.
The annual product quality review procedure was inadequate.
The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
The ongoing stability program for a drug was inadequate.
Extracted automatically from the document of the Health Canada inspection on 2023-01-16. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.
Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.
Click the confirmation button in the email. It's sent from GRM Solutions Brief. If you don't see it, check your spam folder.
Growth stages previewSolve a quiz to start hatching
Your growth record is stored safely in this browser.
